Helix BioPharma's total assets for Q1 2026 were C$19.07M, an increase of 1.40% from the previous quarter. TSE:HBP total liabilities were C$3.00M for the fiscal quarter, a -6.72% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.